Application No.: 10/576,068

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the

application:

LISTING OF CLAIMS:

1. (Currently amended) A method for producing an antibody fragment, comprising

the steps of:

preparing an expression vector comprising a gene encoding a light chain of the

antibody fragment fused with E. coli thermostable enterotoxin signal sequence derivative and a

gene encoding a heavy chain of the antibody fragment fused with E. coli outer membrane protein

A signal sequence, wherein the expression of the genes encoding the light chain and the heavy

chain is regulated by a single promoter;

transforming a microorganism with the expression vector;

3) culturing the transformed microorganism in a medium; and

collecting the antibody fragment secreted from the transformed microorganism

into the medium or from the microorganism.

2. (Original) The method of claim 1, wherein the antibody fragment is derived from

a chimeric antibody, a humanized antibody or a human antibody.

3. (Original) The method of claim 1, wherein the antibody fragment is selected from

the group consisting of Fab, Fab', F(ab'), and scFv.

2

Application No.: 10/576,068

4. (Previously presented) The method of claim 1, wherein the E. coli thermostable

enterotoxin signal sequence derivative has the nucleotide sequence of SEQ ID NO: 17 and the $\it E$.

coli outer membrane protein A signal sequence has the nucleotide sequence of SEQ ID NO: 23.

5. (Previously presented) The method of claim 1, wherein the promoter is T7

promoter or Tac promoter.

6. (Currently amended) The method of claim 1, wherein the antibody fragment is a

fragment of anti-tumor necrosis factor-alpha antibody.

7. (Previously presented) The method of claim 1, wherein the expression vector is

pmsoDLHF_N/S.

8. (Previously presented) The method of claim 1, wherein the microorganism is E.

coli.

9. (Previously presented) The method of claim 8, wherein the microorganism

transformed with the expression vector is E. coli BL21/pmsoDLHF_N/S(HM10924) (KCCM-

10513).

10. (Currently amended) An expression vector comprising a gene encoding a light

chain of the antibody fragment fused with E. coli thermostable enterotoxin signal sequence

derivative and a gene encoding a heavy chain of the antibody fragment fused with E. coli outer

3

Application No.: 10/576,068

membrane protein A signal sequence, wherein the expression of the genes encoding the light

chain and the heavy chain is regulated by a single promotepromoter, and the antibody fragment

expressed from the expression vector is secreted into a culture medium where a host carrying the

expression vector is cultured or into a periplasmic space of the host.

(Previously presented) The expression vector of claim 10, wherein the antibody

fragment is derived from a chimeric antibody, a humanized antibody or a human antibody.

12. (Previously presented) The expression vector of claim 10, wherein the antibody

fragment is selected from the group consisting of Fab, Fab', F(ab'), and scFv.

13. (currently amended): The expression vector of claim 10, wherein the E. coli

thermostable enterotoxing enterotoxin signal sequence derivative has the nucleotide sequence of

SEQ ID NO: 17 and the E. coli outer membrane protein A signal sequence has the nucleotide

sequence of SEO ID NO: 23.

14. (Currently amended) The expression vector of claim 10, wherein the antibody

fragment is a fragment of anti-tumor necrosis factor-alpha antibody.

15. (Previously presented) The expression vector of claim 10, wherein the promoter

is T7 promoter or Tac promoter.

4

Application No.: 10/576,068

 $16. \qquad \hbox{(Previously presented)} \ \ \mbox{The expression vector of claim 15, which is} \\ \mbox{pmsoDLHF N/S.}$

 (Previously presented) A microorganism transformed with the expression vector of claim 10.

18. (Previously presented) The microorganism of claim 17, which is *E. coli*.

(Previously presented) The microorganism of claim 18, which is *E. coli* BL21/pmsoDLHF N/S(HM10924) (KCCM-10513).

Claims 20-43 (Cancelled)